Consent Decree Entered Against Pharmasol
The US District Court for the District of Massachusetts entered a consent decree of permanent injunction against Pharmasol Corporation for distributing adulterated drugs.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
FDA announced on Dec. 14, 2023 that the US District Court for the District of Massachusetts has entered a consent decree of permanent injunction against Pharmasol Corporation and its president, Marc L. Badia, for distributing adulterated drugs. The injunction orders the company to stop distributing products until it complies with requirements under the Federal Food, Drug, and Cosmetic (FD&C) Act. The complaint states the company violated the FD&C Act by distributing drugs through interstate commerce, which do not comply with current good manufacturing practices.
A 2022 inspection of the company’s facilities found repeated violations from a previous 2019 warning letter that include failures to investigate errors, follow written procedures, and adequately clean and maintain equipment. The 2019 warning letter stated customers complained of product leakage, which was not investigated properly by the company.
“When drug manufacturers violate the law and disregard safety standards, they put consumers at significant risk. In this case, the defendant’s company distributed adulterated, poor-quality drugs without regard for patients and consumers,” said Jill Furman, director of the Office of Compliance in FDA’s Center for Drug Evaluation and Research, in an agency press release. “[FDA] plays an important role in protecting consumers, and we will continue to work with our law enforcement partners to pursue and bring into compliance those who do not prioritize the health and safety of the American public.”
Pharmasol, which is under contract with several pharmaceutical companies, manufactures and distributes human and animal prescription drugs and over-the-counter drugs. Products include topical corticosteroids and inhaled anesthetics. Under the consent decree, the company is prohibited from directly or indirectly “manufacturing, preparing, processing, packing, repacking, receiving, labeling, holding and/or distributing any drug, at or from their facilities, unless and until defendants meet certain requirements.”
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
